Colorectal Cancer
Conditions
Brief summary
Patients with stage Ⅰ colorectal cancer or stage Ⅱ colon cancer usually have a good prognosis and are not recommended to receive adjuvant chemotherapy after radical surgery. With the advances in liquid biopsy technology, detection of circulating tumor DNA (ctDNA) can effectively identify early-stage cancer patients with minimal residual disease (MRD) after surgery. According to the growing number of MRD studies in solid tumor, colorectal cancer patients with ctDNA-MRD detection have a poor clinical outcome and are likely to relapse within two years. This study aims to assess the efficacy of adjuvant chemotherapy with capecitabine plus oxaliplatin (CAPEOX) compared with conventional observation in MRD-positive patients with stage I colorectal cancer and clinically low-risk stage II colon cancer.
Interventions
DRUGCapecitabine tablets
Capecitabine 1000 mg/m2, twice daily PO for 14 days, repeat every 3 weeks, for at most 8 cycles.
DRUGOxaliplatin
Oxaliplatin 130 mg/m2 IV day 1, combined with Capecitabine, for at most 8 cycles.
Sponsors
GeneCast Biotechnology Co., Ltd.
Zhejiang University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Colorectal cancer confirmed by pathology, and the TNM stage (AJCC v8) is stage I or stage II. Stage II patients have T3 colonic adenocarcinoma with proficient mismatch-repair system (by immunohistochemistry for four mismatch repair proteins MSH1, MSH2, MSH6, and PMS2) and have no the following clinical risk factors: a) less than 12 lymph nodes examined; b) mucinous carcinoma; c) poor differentiation; d) bowel obstruction or perforation; e) lymphatic/vascular invasion, perineural invasion; f) close, indeterminate, uncertain, positive margins 2. ECOG performance status 0-1 3. No neoadjuvant therapy before surgery 4. Appropriate for active surveillance (i.e., no adjuvant chemotherapy) based on current practice patterns or according to the Chinese Society of Clinical Oncology guidelines for Colorectal Cancer (version 2022) 5. No history of other primary cancers in the past 3 years 6. No history of bone marrow, stem cell or organ transplant 7. Blood samples from 7 to 21 days after surgery were tested positive for ctDNA (tested by MinerVa MRD assay) 8. Pregnancy test done within 14 days before randomization must be negative (for women of childbearing potential only) 9. Voluntarily join the study and sign the informed consent document 10. No unstable or any medical condition that affects patient safety and study compliance evaluated by researchers 11. Availability and provision of adequate surgical tumor tissue for molecular diagnostics
Exclusion criteria
1. Patients with multiple primary colorectal cancers 2. Patients with another primary cancer 3. Patients have the following conditions by blood test, or have obvious contraindication in adjuvant chemotherapy: 1. Moderate/severe renal impairment (GFR\<30 ml/min), as calculated by the Cockcroft and Gault equation 2. Absolute neutrophil count \<1.5×109/L 3. Platelet count \< 75×109/L 4. Hemoglobin \<90 g/L 5. Aspartate aminotransferase/Alanine aminotransferase \>2.5 × upper limit of normal 4. Lactating women 5. Have serious or uncontrolled medical condition that may preclude compliance with the protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence-free survival | 18 months |
Secondary
| Measure | Time frame |
|---|---|
| Clearance of circulating tumor DNA (ctDNA) | 6 months |
Countries
China
Contacts
Primary ContactKefeng Ding, MD, PhD
Backup ContactQian Xiao, MD, PhD
Outcome results
None listed